Core Viewpoint - Tianjin Development (00882) announced that its indirect non-wholly owned subsidiary, Lisheng Pharmaceutical, plans to establish a fund with several partners, aiming to raise a total of RMB 500 million, with Lisheng contributing RMB 174 million, representing 34.75% of the total fund [1] Group 1: Fund Establishment - The fund, tentatively named Jian Sheng Guo Xin Tai Da Equity Fund Partnership (Limited Partnership), has a proposed duration of five years [1] - The fund will primarily invest in the health and biotechnology sectors in China [1] Group 2: Strategic Implications - The potential transaction, if realized, is expected to enhance the group's understanding of the latest developments in the pharmaceutical industry, diversify investment risks, and identify potential strategic partners for future opportunities [1] - The group's investment in the fund is anticipated to provide more industry acquisition opportunities aligned with its development strategy and offer potential returns exceeding fixed income, thereby improving capital allocation efficiency and enhancing capital returns [1]
天津发展(00882)附属拟出资1.74亿元参与设立基金